Archives
-
Atrial Natriuretic Peptide (ANP), Rat: Research Guide
2026-10-02
Atrial Natriuretic Peptide is a cardiac ANP peptide hormone linked to natriuresis, vasodilation, and blood pressure homeostasis. The rat product identified as SKU A1009 requires identity verification because its listed 11-residue sequence does not match the canonical 28-residue mature hormone.
-
α-Linolenic Acid: Design Better Lipid Assays
2026-10-01
α-Linolenic Acid (ALA) is more than an omega-3 substrate: it is a controllable experimental variable linking lipid flux, signaling, and phenotype. This guide shows how to interpret ALA assays alongside recent arachidonic acid immunity research without conflating distinct fatty-acid mechanisms.
-
GOB-38 Biochemistry in Elizabethkingia anophelis
2026-10-01
The reference study characterizes GOB-38, a B3-Q metallo-β-lactamase from Elizabethkingia anophelis, linking its active-site composition with broad β-lactam hydrolysis and possible imipenem preference. Its recombinant-expression, genomic, and co-culture framework shows how enzyme biochemistry can be connected to β-lactam antibiotic resistance research while highlighting the limits of inferring clinical transmission from in vitro data.
-
Nitrocefin Assays for β-Lactamase Research
2026-09-30
Nitrocefin converts β-lactamase hydrolysis into a fast yellow-to-red signal for recombinant enzyme studies, isolate profiling, and inhibitor screening. This practical guide covers assay setup, quantitative readouts, GOB-38-informed design choices, and troubleshooting for reproducible resistance research.
-
Dietary Arachidonic Acid and Humoral Immunity
2026-09-30
The reference study shows that dietary arachidonic acid accelerates rabies vaccine-induced neutralizing antibody production and improves protection in mice, with a corresponding early antibody response observed in human volunteers. Its key mechanistic contribution is to connect lymph-node arachidonic acid metabolism with prostaglandin I2–cAMP–PKA signaling, CD86 expression, AID activation, and germinal-center B-cell responses.
-
Stable Cationic Liposomes for mRNA Cancer Vaccines
2026-09-29
Pedersen and colleagues describe a simple CAF04–mRNA platform in which a preformulated cationic liposome system is admixed with antigen-encoding mRNA immediately before use. In a murine lymphoma model, formulation-dependent particle properties were associated with potent CD8+ T-cell responses, delayed tumor growth, and improved survival, while the platform also offered freeze-drying and storage advantages.
-
Tamoxifen: Reliable Design for Viability Assays
2026-09-29
This scenario-based guide explains how Tamoxifen (SKU B5965) can be integrated into cell viability, proliferation, cytotoxicity, and CreER workflows while controlling solvent, interpretation, and storage variables. It connects mechanistic evidence with practical preparation guidance for more defensible laboratory comparisons.
-
Sulfachloropyridazine: From DHPS to Translational Insight
2026-09-28
Sulfachloropyridazine offers translational researchers a practical bridge from dihydropteroate synthase inhibition to antimicrobial phenotyping, infection biology, and microbiome-aware study design. This article explains how to build evidence across enzyme assays, susceptibility testing, and host-associated microbial ecology without mistaking antibacterial activity for whole-system efficacy.
-
TCAIM Lowers OGDH to Reprogram Mitochondrial Metabolism
2026-09-28
The study identifies mitochondrial TCAIM as a DNAJC co-chaperone that binds native OGDH and, through HSPA9 and LONP1, reduces OGDH protein abundance and complex activity. The findings establish a proteostasis-based route for adjusting mitochondrial metabolism, while also highlighting why perturbations at other mitochondrial sites should be interpreted as distinct experimental mechanisms.
-
Chloroquine as a Probe of Itch-Circuit Sensitization
2026-09-27
Use Chloroquine as a functional probe for MrgprA3+ pruriceptive neurons—not as a treatment for chronic dermatitis—to help separate itch-circuit activity from TRPV1-linked sensitization. This workflow pairs controlled neuronal assays with behavioral and tissue-level readouts, while highlighting formulation and interpretation pitfalls.
-
AAPH in Protein Oxidation: A Practical Assay Guide
2026-09-26
Use AAPH to create sustained, water-compatible peroxyl-radical stress and examine how oxidation changes protein functionality—not just whether a sample is damaged. A hazelnut-protein study found a functional-property peak at 1.0 mmol/L AAPH, while also showing why dose selection and gel readouts must be optimized together.
-
ASB3 Targets MAVS to Suppress Antiviral Immunity
2026-09-25
The 2024 study identifies ASB3 as an E3 ubiquitin ligase that limits RNA-virus-triggered type I interferon responses by promoting K48-linked ubiquitination and proteasomal degradation of MAVS. Cell and animal findings connect this molecular mechanism to susceptibility to influenza infection, while highlighting questions about the conditions and pathways that determine ASB3 activity.
-
Cytoskeleton Dependence of Mechanical Autophagy
2026-09-25
The study shows that cytoskeletal microfilaments are required for compression-induced changes in autophagosome abundance, while microtubules make an auxiliary contribution. Its central implication is that the cytoskeleton is not merely a structural backdrop: it is part of the machinery that links mechanical input to an autophagy response, although the experiments do not establish every step of that signaling pathway.
-
FDA-Approved Bioactive Compound Library: L1021
2026-09-24
Practical guidance for using DiscoveryProbe™ FDA-approved Drug Library (SKU: L1021) in cell-viability, proliferation, and cytotoxicity screening. Learn how to control DMSO, plan follow-up assays, interpret hits cautiously, and assess library usability using documented product details and relevant research.
-
Chloroquine Pharmacogenomics: Evidence and Risks
2026-09-24
This systematic review maps the limited pharmacogenomic evidence for chloroquine and hydroxychloroquine, identifying CYP2C8, CYP3A4/5, and CYP2D6 variation as potential sources of differences in drug safety and effectiveness. Its risk-phenotype framework highlights possible clinical relevance across populations, while the small evidence base means that prospective validation is still needed before genotype-guided decisions can be considered established.